212 related articles for article (PubMed ID: 10888269)
1. Adjuvant histamine in cancer immunotherapy.
Hellstrand K; Hansson M; Hermodsson S
Semin Cancer Biol; 2000 Feb; 10(1):29-39. PubMed ID: 10888269
[TBL] [Abstract][Full Text] [Related]
2. Addition of histamine to interleukin 2 treatment augments type 1 T-cell responses in patients with melanoma in vivo: immunologic results from a randomized clinical trial of interleukin 2 with or without histamine (MP 104).
Asemissen AM; Scheibenbogen C; Letsch A; Hellstrand K; Thorén F; Gehlsen K; Schmittel A; Thiel E; Keilholz U
Clin Cancer Res; 2005 Jan; 11(1):290-7. PubMed ID: 15671558
[TBL] [Abstract][Full Text] [Related]
3. Post-consolidation immunotherapy with histamine dihydrochloride and interleukin-2 in AML.
Romero AI; Thorén FB; Aurelius J; Askarieh G; Brune M; Hellstrand K
Scand J Immunol; 2009 Sep; 70(3):194-205. PubMed ID: 19703009
[TBL] [Abstract][Full Text] [Related]
4. Histamine dihydrochloride and low-dose interleukin-2 as post-consolidation immunotherapy in acute myeloid leukemia.
Thorén FB; Romero AI; Brune M; Hellstrand K
Expert Opin Biol Ther; 2009 Sep; 9(9):1217-23. PubMed ID: 19653866
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy with histamine dihydrochloride for the prevention of relapse in acute myeloid leukemia.
Martner A; Thorén FB; Aurelius J; Söderholm J; Brune M; Hellstrand K
Expert Rev Hematol; 2010 Aug; 3(4):381-91. PubMed ID: 21083028
[TBL] [Abstract][Full Text] [Related]
6. IL-15: targeting CD8+ T cells for immunotherapy.
Diab A; Cohen AD; Alpdogan O; Perales MA
Cytotherapy; 2005; 7(1):23-35. PubMed ID: 16040381
[TBL] [Abstract][Full Text] [Related]
7. Histamine in cancer immunotherapy: a preclinical background.
Hellstrand K
Semin Oncol; 2002 Jun; 29(3 Suppl 7):35-40. PubMed ID: 12068387
[TBL] [Abstract][Full Text] [Related]
8. Histamine: a novel approach to cancer immunotherapy.
Hellstrand K; Brune M; Naredi P; Mellqvist UH; Hansson M; Gehlsen KR; Hermodsson S
Cancer Invest; 2000; 18(4):347-55. PubMed ID: 10808371
[TBL] [Abstract][Full Text] [Related]
9. Multiparametric flow cytometric analysis of signal transducer and activator of transcription 5 phosphorylation in immune cell subsets in vitro and following interleukin-2 immunotherapy.
Varker KA; Kondadasula SV; Go MR; Lesinski GB; Ghosh-Berkebile R; Lehman A; Monk JP; Olencki T; Kendra K; Carson WE
Clin Cancer Res; 2006 Oct; 12(19):5850-8. PubMed ID: 17020993
[TBL] [Abstract][Full Text] [Related]
10. T cells take aim at cancer.
Pardoll D
Proc Natl Acad Sci U S A; 2002 Dec; 99(25):15840-2. PubMed ID: 12461164
[No Abstract] [Full Text] [Related]
11. Twelve immunotherapy drugs that could cure cancers.
Cheever MA
Immunol Rev; 2008 Apr; 222():357-68. PubMed ID: 18364014
[TBL] [Abstract][Full Text] [Related]
12. [Antitumoral action of interferons and interleukins in combination with radiotherapy. Part I: immunologic basis].
Herskind C; Fleckenstein K; Lohr J; Li CY; Wenz F; Lohr F
Strahlenther Onkol; 2004 Apr; 180(4):187-93. PubMed ID: 15057428
[TBL] [Abstract][Full Text] [Related]
13. Synergistic interleukin-18 and low-dose interleukin-2 promote regression of established murine neuroblastoma in vivo.
Redlinger RE; Mailliard RB; Lotze MT; Barksdale EM
J Pediatr Surg; 2003 Mar; 38(3):301-7; discussion 301-7. PubMed ID: 12632339
[TBL] [Abstract][Full Text] [Related]
14. [Prospects for cancer immunotherapy using interleukin-1(IL-1) and interleukin-2(IL-2)].
Okuno K
Nihon Rinsho; 1983; 41(4):868-74. PubMed ID: 6350655
[No Abstract] [Full Text] [Related]
15. In vivo expansion of activated naive CD8+ T cells and NK cells driven by complexes of IL-2 and anti-IL-2 monoclonal antibody as novel approach of cancer immunotherapy.
Tomala J; Chmelova H; Mrkvan T; Rihova B; Kovar M
J Immunol; 2009 Oct; 183(8):4904-12. PubMed ID: 19801515
[TBL] [Abstract][Full Text] [Related]
16. B-cell depletion using an anti-CD20 antibody augments antitumor immune responses and immunotherapy in nonhematopoetic murine tumor models.
Kim S; Fridlender ZG; Dunn R; Kehry MR; Kapoor V; Blouin A; Kaiser LR; Albelda SM
J Immunother; 2008 Jun; 31(5):446-57. PubMed ID: 18463540
[TBL] [Abstract][Full Text] [Related]
17. Molecular immunological approaches to biotherapy of human cancers--a review, hypothesis and implications.
Becker Y
Anticancer Res; 2006; 26(2A):1113-34. PubMed ID: 16619514
[TBL] [Abstract][Full Text] [Related]
18. Alleviating oxidative stress in cancer immunotherapy: a role for histamine?
Hellstrand K; Brune M; Dahlgren C; Hansson M; Hermodsson S; Lindnér P; Mellqvist UH; Naredi P
Med Oncol; 2000 Nov; 17(4):258-69. PubMed ID: 11114704
[TBL] [Abstract][Full Text] [Related]
19. Adoptive cellular immunotherapy of cancer.
Winter H; Fox BA
Curr Opin Mol Ther; 1999 Feb; 1(1):89-97. PubMed ID: 11249690
[No Abstract] [Full Text] [Related]
20. Natural killer cell-based immunotherapy in cancer: current insights and future prospects.
Sutlu T; Alici E
J Intern Med; 2009 Aug; 266(2):154-81. PubMed ID: 19614820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
